There is no adequate competition, this is an orphan drug that will sustain at most one producer. Fun fact: most generics are sourced to very few producers because margins are so low, competition is working.

There are similarities to fine chemical shortages: http://blogs.sciencemag.org/pipeline/archives/2010/06/16/spa...

The world can do without sparteine, but orphan drugs call for regulation as natural monopolies, or even government subsidies.